The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

doi:10.1158/1078-0432.CCR-17-2289

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2018

Aisner Dara L, Sholl Lynette M, Berry Lynne D, Rossi Michael R, Chen Heidi, Fujimoto Junya, Moreira Andre L, Ramalingam Suresh S, Villaruz Liza C, Otterson Gregory A, Haura Eric, Politi Katerina, Glisson Bonnie, Cetnar Jeremy, Garon Edward B, Schiller Joan, Waqar Saiama N, Sequist Lecia V, Brahmer Julie, Shyr Yu, Kugler Kelly, Wistuba Ignacio I, Johnson Bruce E, Minna John D, Kris Mark G, Bunn Paul A, Kwiatkowski David J

Abstract excerpt

Purpose: Multiplex genomic profiling is standard of care for patients with advanced lung adenocarcinomas. The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas.Experimental Design: Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14...

Topics

Adenocarcinoma of Lung
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Biomarkers, Tumor
Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

DNA Mutational Analysis

Female

High-Throughput Nucleotide Sequencing

Humans

Lung Neoplasms

Male

Middle Aged

Molecular Targeted Therapy

Mutation

Prognosis

Prospective Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 29217530
DOI: 10.1158/1078-0432.CCR-17-2289
PMCID: PMC7008001

Genes

ALK
EGFR
ROS1
BRAF
ERBB2
MET
RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-29217530-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).PMID 29217530Read ↗

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.Semantic proximity Read ↗

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation ConsortiumSemantic proximity Read ↗

Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.Semantic proximity Read ↗

The impact of genomic changes on treatment of lung cancer.Semantic proximity Read ↗

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Semantic proximity Read ↗

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.Semantic proximity Read ↗

Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.